Clinical utility of repeated rebiopsy for EGFR T790M mutation detection in non-small cell lung cancer
In this study, among patients who initially tested negative for T790M in rebiopsy, repeated rebiopsies uncovered an additional 23.5% T790M positivity. Particularly, it is suggested that repeated rebiopsies may be valuable for patients with prolonged EGFR TKI usage, better responses to treatment, and bone metastasis.
Authors
- Chi Young Kim (ORCID: https://orcid.org/0000-0003-3037-206X)
- Se Hyun Kwak (ORCID: https://orcid.org/0000-0002-5680-111X)
- Yoon Soo Chang (ORCID: https://orcid.org/0000-0003-3340-4223)
- Seok‐Jae Heo (ORCID: https://orcid.org/0000-0002-8764-7995)
- Kyeong Yeon Kim
- Sang Hoon Lee (ORCID: https://orcid.org/0000-0002-7706-5318)
- Eun Young Kim (ORCID: https://orcid.org/0000-0002-3281-5744)
- Eun Hye Lee (ORCID: https://orcid.org/0000-0003-2570-3442)
Institutions
- Yonsei University (KR)
- Severance Hospital (KR)
- Gangnam Severance Hospital (KR)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-08-26
- DOI
- https://doi.org/10.3389/fonc.2024.1452947
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea